Metabolic Syndrome as a Factor Affecting Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a systemic disease which may be associated with other comorbidities. The aim of the study was to estimate the incidence of metabolic syndrome (MS) in COPD patients and to assess its impact on systemic inflammation and lung function. MS was diagnosed in accordance with the recommendations of the Polish Forum for the Prevention of Cardiovascular Diseases. The study group consisted of 267 patients with stable COPD in all stages of severity. All patients underwent spirometry with bronchial reversibility testing and 6 min walk test (6MWT). The following blood tests were evaluated: lipid profile, glucose and C-reactive protein as well as serum concentration of IL-6, leptin, adiponectin, and endothelin. MS was diagnosed in 93 patients (35.8%). No differences were observed in the incidence of MS in relation to airflow limitation severity (mild; moderate; severe and very severe: 38.9; 36.3; 35.2 and 25.0%, respectively). FEV1 (% predicted), FVC (% predicted), 6MWT distance (6MWD), age, and the number of pack-years were similar in patients with and without MS. MS was more frequent in males than females (38.7 vs. 28.4%, p > 0.05). Serum concentrations of IL-6, endothelin, leptin, and CRP were higher in the MS group, contrary to adiponectin concentration which was lower (p < 0.01). MS was more frequent in male COPD patients, but there were no differences in its frequency between patients with different severity of airflow limitation. We conclude that MS, as a comorbidity, occurs in all COPD stages and affects systemic inflammation. MS incidence does not depend on COPD severity.
KeywordsAdiponectin Bronchial reversibility test Comorbidities Endothelin Interleukin 6 Lung disease Spirometry
The study was performed as the part of National Center for Research and Development project ‘Chronic obstructive pulmonary disease (COPD) – systemic disease; the biggest threat of twenty-first century’ (NR 13 0034 06/2009).
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
- Corbaton-Anchuelo A, Martinez-Larrad MT, Fernandez-Perez C, Vega-Quiroga S, Ibarra-Rueda JM, Serrano-Rios M (2013) Metabolic syndrome, adiponectin, and cardiovascular risk in Spain (the Segovia study): impact of consensus societies criteria. Metab Syndr Relat Disord 11:309–318CrossRefPubMedGoogle Scholar
- Díez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, López García F, Montero L, Soriano JB, Working Group on COPD; Spanish Society of Internal Medicine (2014) COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 4:419–425CrossRefGoogle Scholar
- GOLD (2016) Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease. http://goldcopd.org. Accessed on 1 Feb 2017
- International Diabetes Federation (2006) IDF consensus worldwide definition of the metabolic syndrome. https://www.idf.org/metabolic-syndrome. Accessed on 1 Feb 2017
- Mamcarz A, Podolec P, Kopeć G, Czarnecka D, Rynkiewicz A, Stańczyk J, Undas A, Godycki-Ćwirko M, Kozek E, Pająk A, Naruszewicz M, Opala G, Grzeszczak W, Windaket A (2009) Guidelines for metabolic syndrome diagnosis of polish forum for the prevention of cardiovascular diseases. Forum Profilaktyki 2:1–3Google Scholar
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force (2005) Standardisation of spirometry. Europ Respir J 26:319–338CrossRefGoogle Scholar
- Minas M, Kostikas K, Papaioannou AI, Mystridou P, Karetsi E, Georgoulias P, Liakos N, Pournaras S, Gourgoulianis KI (2011) The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD 8:414–420CrossRefPubMedGoogle Scholar
- Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and nutrition examination survey, 1988–1994. Arch Intern Med 163:427–436CrossRefPubMedPubMedCentralGoogle Scholar
- Sato M, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, Aida Y, Kishi H, Nunomiya K, Nakano H, Sato K, Watanabe T, Konta T, Ueno Y, Kato T, Kayama T, Kubota I (2013) Retrospective analysis of the relationship between decline in FEV(1) and abdominal circumference in male smokers: the Takahata study. Int J Med Sci 10:1–7CrossRefPubMedGoogle Scholar
- van den Borst B, Gosker HR, Koster A, Yu B, Kritchevsky SB, Liu Y, Meibohm B, Rice TB, Shlipak M, Yende S, Harris TB (2012) The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr 96:516–526CrossRefPubMedPubMedCentralGoogle Scholar